Prostate cancer diagnostics

Prostate cancer is a major public health concern. Approximately 1 man in 7 will be diagnosed with prostate cancer in his lifetime.1 This makes prostate cancer the second most common cancer and the sixth most common cause of death from cancer in men worldwide.2 Approximately 70% of prostate cancer cases are low risk, yet up to 90% are treated aggressively.3

Recent translational research is showing that much like soft tissue cancers, prostate cancer can now be molecularly subtyped with immunohistochemistry techniques, which may enable the identification of aggressive versus indolent disease. We are committed to the development of innovative tools to better identify and subtype prostate cancer—so you can deliver the right test, with confidence, in the shortest possible time.

VENTANA Basal Cell Cocktail (34βE12+p63) is an antibody cocktail of p63 (4A4) and keratin (34βE12). It may be used to aid in the differentiation of benign lesions with basal cells from malignant prostate lesions lacking basal cells.

“Basal Cell Cocktail not only increases the sensitivity of the basal cell detection, but also reduces the staining variability and therefore renders the basal cell immunostaining more consistent. We recommend this Basal Cell Cocktail for routine PCA diagnostic work-up.”4

 

Research has demonstrated that the TMPRESS2:ERG rearrangement occurs in approximately 50% of prostate cancer patients, does not occur in normal tissue and describes a molecular subtype that is associated with androgen-driven prostate cancer.5,6,7

The ERG (EPR 3864) Rabbit Monoclonal Primary Antibody is capable of detecting:

  • Truncated ERG resulting from TMPRSS2:ERG (or other ERG gene fusions)
  • Wild type ERG (most notably expressed in vessel endothelium)

See all Prostate Markers

Virtual-slide-box-tour

Virtual Slide Box Tour

Click here to learn more

 

 

  1. American Cancer Society. What are the key statistics about prostate cancer? American Cancer Society Website. http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. Revised 14 Dec 2012. Accessed 9 Nov 2012.

  2. Cancer Research UK. Prostate Cancer. http://www.cancerresearchuk.org/cancer-info/cancerstats/world/prostate-cancer-world/

  3. Hayes et al. Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer A Decision Analysis. JAMA. 2010; 304(21): 2373-2380. doi:10.1001/jama.2010.1720.

  4. Zhou M et al. Basal cell cocktail (34betae12 + p63) improves the detection of prostate basal cells. AM J Surg Pathol. 2003; 27: 365-71.

  5. Shah R B, et al. The diagnostic use of ERG in resolving an “atypical glands suspicious for cancer” diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoAracemase markers. Human pathology. 2013; 44(5): 786 -794.

  6. Weischenfeldt et al. Integrative Genomic Analyses Reveal an Androgen-Driven Somatic Alteration Landscape in Early-Onset Prostate Cancer. Cancer Cell. 2013; 23:159-170.

  7. Park, K et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010; 12(7): 590.